These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 28342534)

  • 21. Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity: results from UNCOVER-2 and UNCOVER-3.
    Kemény L; Berggren L; Dossenbach M; Dutronc Y; Paul C
    J Dermatolog Treat; 2019 Feb; 30(1):19-26. PubMed ID: 29726739
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes.
    Puig L; Dossenbach M; Berggren L; Ljungberg A; Zachariae C
    Acta Derm Venereol; 2019 Oct; 99(11):971-977. PubMed ID: 31240322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term Extension.
    Kimball AB; Luger T; Gottlieb A; Puig L; Kaufmann R; Burge R; Lin CY; Yosipovitch G
    Acta Derm Venereol; 2018 Jan; 98(1):98-102. PubMed ID: 28929168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis.
    Al Sawah S; Foster SA; Burge R; Amato D; Schacht A; Zhu B; Hartz S; Leonardi C
    J Med Econ; 2017 Dec; 20(12):1224-1230. PubMed ID: 28760056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate-to-severe psoriasis patients: 12-week results from two phase III trials.
    Paul C; Guenther L; Torii H; Sofen H; Burge R; Lin CY; Potts Bleakman A; Mallbris L; Poulin Y
    J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):68-72. PubMed ID: 28881462
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis: Subgroup analysis of a placebo-controlled, phase 3 study (UNCOVER-1).
    Imafuku S; Torisu-Itakura H; Nishikawa A; Zhao F; Cameron GS;
    J Dermatol; 2017 Nov; 44(11):1285-1290. PubMed ID: 28635026
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of etanercept therapy on psoriasis symptoms in patients from Latin America, Central Europe, and Asia: a subset analysis of the PRISTINE trial.
    Kemeny L; Amaya M; Cetkovska P; Rajatanavin N; Lee WR; Szumski A; Marshall L; Mahgoub EY; Aldinç E
    BMC Dermatol; 2015 May; 15():9. PubMed ID: 25994179
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.
    Gordon KB; Leonardi CL; Lebwohl M; Blauvelt A; Cameron GS; Braun D; Erickson J; Heffernan M
    J Am Acad Dermatol; 2014 Dec; 71(6):1176-82. PubMed ID: 25242558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial.
    Blauvelt A; Lebwohl MG; Mabuchi T; Leung A; Garrelts A; Crane H; ElMaraghy H; Patel H; Ridenour T; See K; Gallo G; Paul C
    J Am Acad Dermatol; 2021 Aug; 85(2):360-368. PubMed ID: 33253833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
    Saeki H; Nakagawa H; Nakajo K; Ishii T; Morisaki Y; Aoki T; Cameron GS; Osuntokun OO;
    J Dermatol; 2017 Apr; 44(4):355-362. PubMed ID: 27726163
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis.
    Ryan C; Menter A; Guenther L; Blauvelt A; Bissonnette R; Meeuwis K; Sullivan J; Cather JC; Yosipovitch G; Gottlieb AB; Merola JF; Callis Duffin K; Fretzin S; Osuntokun OO; Burge R; Naegeli AN; Yang FE; Lin CY; Todd K; Potts Bleakman A;
    Br J Dermatol; 2018 Oct; 179(4):844-852. PubMed ID: 29747232
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial.
    Deodhar A; van der Heijde D; Gensler LS; Kim TH; Maksymowych WP; Østergaard M; Poddubnyy D; Marzo-Ortega H; Bessette L; Tomita T; Leung A; Hojnik M; Gallo G; Li X; Adams D; Carlier H; Sieper J;
    Lancet; 2020 Jan; 395(10217):53-64. PubMed ID: 31813637
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis.
    Papp KA; Bachelez H; Blauvelt A; Winthrop KL; Romiti R; Ohtsuki M; Acharya N; Braun DK; Mallbris L; Zhao F; Xu W; Walls CD; Strober B
    Br J Dermatol; 2017 Dec; 177(6):1537-1551. PubMed ID: 28600810
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term efficacy and safety results from an open-label phase III study (UNCOVER-J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab.
    Umezawa Y; Torisu-Itakura H; Morisaki Y; ElMaraghy H; Nakajo K; Akashi N; Saeki H;
    J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):568-576. PubMed ID: 30325534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis.
    Langley RGB; Reich K; Strand V; Feldman SR; Paul C; Gordon K; Warren RB; Toth D; Nikaï E; Zhu B; Goldblum O; Edson-Heredia E; Carlier H; Burge R; Lin CY; Hollister K; Augustin M
    Qual Life Res; 2020 Feb; 29(2):369-380. PubMed ID: 31655974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study.
    Leonardi C; Maari C; Philipp S; Goldblum O; Zhang L; Burkhardt N; Ball S; Mallbris L; Gonzalez P; Fernández-Peñas P; Puig L
    J Am Acad Dermatol; 2018 Nov; 79(5):824-830.e2. PubMed ID: 29803904
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An indirect comparison of long-term efficacy of every-2-week dosing vs. recommended dosing of ixekizumab in patients who had static Physician's Global Assessment > 1 at week 12.
    Papp K; Maari C; Cauthen A; Gooderham M; Spelman L; Yamanaka K; Polzer P; Zhang L; Osuntokun O; Augustin M
    Br J Dermatol; 2020 Jul; 183(1):52-59. PubMed ID: 31545506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial.
    Augustin M; Reich K; Yamauchi P; Pinter A; Bagel J; Dahale S; You R; Bruin G; Djimopoulos J; Paguet B; Charef P; Patekar M; Keefe D
    Br J Dermatol; 2022 Jun; 186(6):942-954. PubMed ID: 34981829
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3.
    Egeberg A; Wu JJ; Korman N; Solomon JA; Goldblum O; Zhao F; Mallbris L
    J Am Acad Dermatol; 2018 Jul; 79(1):104-109.e8. PubMed ID: 29548945
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.